For example, a reduced benefit of EGFR‐TKI therapy has been associated with increasing levels of sensitizing mutations in ctDNA, likely reflecting an increase in systemic tumor burden and/or overall tumor activity.9 This evidence concerns the gene EGFR and neoplasm.